Assessment for ease of use and preference of a new prefilled insulin pen (FlexTouch Degludec U100/U200) versus the SoloSTAR insulin pen by patients with diabetes and healthcare professionals

Bibliography

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(Suppl 1):S55-60
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in Type 2 Diabetes: a patients-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1365-79
   Google Scholar
• Korytkowski M, Bell D, Jocobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-48
   PubMed Web of Science ®Google Scholar
• Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 2004;27:2495-7
   PubMed Web of Science ®Google Scholar
• Pfützner A, Bailey T, Campos C, et al. Accuracy and preference assessment of prefilled insulin pen versus vial and syringe with diabetes patients, caregivers and healthcare professionals. Curr Med Res Opin 2013;29:475-81
   PubMed Web of Science ®Google Scholar
• Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors and a pump. Clin Pediatr 2004;43:69-74
   PubMed Web of Science ®Google Scholar
• Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999;22:137-40
   PubMed Web of Science ®Google Scholar
• Hemmingsen H, Niemeyer M, Hansen MR, et al. A prefilled insulin pen with a novel injection mechanism and lower injection force than other prefilled pens. Diabetes Technol Ther 2011;13:1207-11
   PubMed Web of Science ®Google Scholar
• Wielandt JO, Niemeyer M, Hansen MR, et al. An assessment of dose accuracy and injection force of a novel prefilled insulin pen: comparison with a widely-used prefilled insulin pen. Expert Opin Drug Deliv 2011;8:1271-6
   PubMed Web of Science ®Google Scholar
• Wielandt JO, Niemeyer M, Hansen MR, et al. FlexTouch: a prefilled insulin pen with a novel injection mechanism with consistent high accuracy at low-(1U), medium- (40U), and high-(80U) dose settings. J Diabetes Sci Tech 2011;5:1195-9
   PubMedGoogle Scholar
• Bailey T, Thurman J, Niemeyer M, Schmeisl G. Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr Med Res Opin 2011;27:2043-52
   PubMed Web of Science ®Google Scholar
• Nadeau DA, Campos C, Niemayer M, Bailey T. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr Med Res Opin 2012;28:1-11
   Web of Science ®Google Scholar
• Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64
   PubMed Web of Science ®Google Scholar
• Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care 2013;36(4):858-64
   PubMed Web of Science ®Google Scholar
• Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013;98(3):1154-62
   PubMed Web of Science ®Google Scholar
• Ratner RE, Gough SCL, Mathieu C, et al. Hypoglycaemia risk wirh insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.Diabetes Obes Metab. 2013;15:175-84
   Google Scholar
• National Diabetes Statistics 2011. National Institute of Diabetes Digestive and Kidney Diseases. Available from: http://diabetes.niddk.nih.gov/dm/pubs/overview [Last accessed 31 January 2014]
   Google Scholar
• Gough SCL, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 U/mL once daily improves glycaemic control similar to insulin glargine with a low risk of hypoglycemica in insulin-naive patients with type 2 diabetes mellitus: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536-42
   PubMed Web of Science ®Google Scholar
• Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes. Clin Ther 2004;26:531-40
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care 2005;28:2543-5
   PubMed Web of Science ®Google Scholar
• Pfützner J, Hellhammer J, Musholt P, et al. Evaluation of dexterity in insulin-treated patients with type 1 and type 2 diabetes mellitus. Diabetes Sci Technol 2011;5:158-65
   PubMedGoogle Scholar
• Loseth S, Mellgren SI, Jorde R, et al. Polyneuropathy in type 1 and type 2 diabetes: comparison of nerve conduction studies, thermal perception thresholds and intrepidermal nerve fibre densities. Diabetes Metab Res Rev 2010;26:100-6
   PubMed Web of Science ®Google Scholar
• Miralles-Garcia JM, de Pablos-Velasco P, Cabrerizo L, et al. Prevalence of distal diabetic polyneuropathy using quantitative sensory methods in a population with diabetes of more than 10 years’ duration. Endocrinol Nutr 2010;57:414-20
   PubMedGoogle Scholar
• Pfützner A, Musholt PB, Schipper C, et al. Self-assessment and objective determination of dexterity in patients with type 1 or type 2 diabetes mellitus. Curr Med Res Opin 2012;28:15-21
   PubMed Web of Science ®Google Scholar
• Pfützner A, Schipper C, Niemeyer M, et al. Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills. J Diabetes Sci Technol 2012;6:910-16
   PubMedGoogle Scholar
• Rodbard H, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinoogy consensus panel on type 2 diabetes mellitis: an algorithm for glycaemic control. Endocr Pract 2009;15(6):540-59
   PubMed Web of Science ®Google Scholar
• Crasto W, Jarvis J, Hackett E, et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad Med J 2009;85:219-22
   PubMed Web of Science ®Google Scholar